Coronavirus Latest News

Easier distribution may make Moderna’s vaccine much more valuable | Nils Pratley

While Pfizer/BioNTech’s version requires -75C storage, Moderna’s could be easier to roll out

A second coronavirus vaccine candidate was always likely to struggle to match the excitement of the first, at least in stock market terms. Sure enough, Moderna’s promising trial results merely added to the generally bullish mood in markets without generating the same sense of wild relief, and 5% rise in the FTSE 100 index, that Pfizer and BioNTech achieved a week ago.

But, actually, the key difference with Moderna’s version looks significant. It’s the fact the company says its vaccine can be transported and stored for up to six months at -20C and will then remain stable for 30 days at fridge temperatures. By contrast, Pfizer and BioNTech spoke about -75C in storage and then only five days of stability in conventional fridges.

Continue reading…

Read the original article at The Guardian

Related Articles

Back to top button
Close